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Introduction
The ubiquitin-proteasome system regulates turnover of proteins involved in apoptosis, proliferation, and signal transduction [1] [2] [3] . Cullin-RING ligases (CRLs), the largest subfamily of E3 ubiquitin ligases, target proteins for proteasomal degradation through the addition of polyubiquitin chains [2] . CRL activation via conjugation to the small ubiquitin-like protein NEDD8 (neural precursor cell expressed, developmentally downregulated 8) is regulated by NEDD8-activating enzyme (NAE). CRLs and associated regulatory proteins are attractive novel targets for the development of antitumor agents [2, 3] .
Pevonedistat (TAK-924/MLN4924) is a first-in-class, investigational, small-molecule NAE inhibitor that covalently binds to NEDD8, leading to apoptotic cell death. Pevonedistat has shown single-agent activity in various human solid tumor cell lines and xenograft models, as well as in patients with advanced solid tumors and hematologic malignancies [2, [4] [5] [6] [7] [8] [9] [10] [11] [12] . Pevonedistat delays completion of platinum-induced DNA repair in a transcription-coupled nucleotide excision repair (NER) and interstrand crosslink repair (ICR) pathway−dependent mechanism [13] . Excision repair cross-complementation group 1 (ERCC1), a component of the NER pathway, is thought to be involved in resistance to platinum-based therapies [14, 15] and predictive of decreased efficacy of platinum therapy [16] [17] [18] [19] [20] [21] . Pevonedistat enhances the antitumor activity of taxanes and gemcitabine, is synergistic with platinum salts, and is active in platinum-resistant tumors [13, [22] [23] [24] .
The safety and activity of pevonedistat monotherapy were investigated in a phase I study in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), which demonstrated that treatment was feasible with clinical activity [11] . Additionally, the efficacy and safety of pevonedistat in combination with the standard-of-care agent azacitidine have been investigated in treatment-naïve patients with AML (ClinicalTrials.gov identifier NCT01814826) [25] . Phase II and III studies of pevonedistat in combination with azacitidine in high-risk MDS, chronic myelomonocytic leukemia, or lowblast count AML are currently ongoing (ClinicalTrials.gov identifiers NCT02610777 and NCT03268954). To further explore the role of pevonedistat in combination with standardof-care chemotherapies, this phase Ib study aimed to determine the maximum tolerated dose (MTD) and assess the safety, tolerability, and pharmacokinetics of pevonedistat in combination with docetaxel, carboplatin plus paclitaxel, or gemcitabine in patients with advanced solid tumors. The expression of ERCC1 as a candidate biomarker of response to treatment with pevonedistat in combination with carboplatin plus paclitaxel therapy was also investigated.
Methods

Study design and patients
This was an open-label, multicenter, phase Ib, dose-escalation study of pevonedistat in combination with either docetaxel (arm 1), carboplatin plus paclitaxel (arm 2), or gemcitabine (arm 3) in adult patients with confirmed solid tumors who had progressed despite standard therapy or for whom conventional therapy was considered ineffective (ClinicalTrials.gov identifier NCT01862328; Online Resource: Supplementary  Fig. 1 a) Planned pevonedistat doses were higher in arm 3 (versus arm 1 and arm 2) but administration was on a weekly schedule (versus three times a week in arm 1 and arm 2) to match the dosing schedule of gemcitabine, to ensure exposure to both drugs and leverage the mechanism of action of the two drugs. Full dosing details are included in the Online Resource.
Pevonedistat dose escalation (Online Resource: Supplementary Fig. 1 b) proceeded via an adaptive Bayesian continual reassessment method (CRM) based on cycle 1 DLTs (Online Resource). Upon MTD determination in each arm, additional patients were enrolled to confirm the MTD (MTD expansion cohorts). Patients were treated for up to 12 cycles or until disease progression or unacceptable toxicity. Patients with clinical benefit could continue with combination treatment or singleagent pevonedistat beyond 12 cycles.
The primary objective was to establish the MTD of pevonedistat in combination with docetaxel, with carboplatin plus paclitaxel, and with gemcitabine. Secondary objectives included disease response and pharmacokinetics of pevonedistat plus standard-of-care regimens. An exploratory objective was to identify potential biomarkers of response to pevonedistat-containing therapy, including tumor ERCC1 expression.
Assessments
Adverse events (AEs) were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. DLT determination criteria are described in the Online Resource. Investigatorassessed tumor responses were based on Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 [26] . Response assessment methods are described in the Online Resource. Blood sampling methods for pharmacokinetic analyses, immunohistochemistry and ERCC1 expression evaluation methods, and statistical methods are reported in the Online Resource.
Results
Patients
At data cutoff (01 April 2016), 64 patients had been enrolled (22 in arm 1, six in arm 2a, 26 in arm 2, and 10 in arm 3) and had received at least one dose of study drug. Patient demographics and baseline characteristics were generally similar between arms ( 
DLTs and MTD
Fifty-six (88%) patients were included in the DLT-evaluable population ( . As the predicted MTD was between the mid low (17.5 mg/m 2 ) and mid high (22.5 mg/m 2 ) (see the Online Resource) and because at least six patients had been enrolled at the 20 mg/m 2 dose, the CRM algorithm did not suggest further dose escalation or de-escalation and the MTD was declared as 20 mg/m 2 (Online Resource: Supplementary  Fig. 1 b) . Six additional patients were enrolled at this dose (expansion phase) for a total of 12 patients receiving pevonedistat at the MTD (20 mg/m 2 ) in combination with paclitaxel plus carboplatin; one of these six patients reported a DLT (grade 3 increased AST), confirming the MTD in this arm.
In arm 3, eight patients enrolled at the initial dose of pevonedistat 25 mg/m 2 were DLT evaluable and three experienced a DLT: one had grade 3 increased ALT and AST, one had grade 4 febrile neutropenia and withdrew from the study, and one had grade 3 febrile neutropenia, withdrew from the study, and died from complications of febrile neutropenia. Due to the number of DLTs observed in this arm, and based on two patients missing >1 treatment dose in cycle 1, as well as the need to delay therapy in cycle 2 to allow recovery from gemcitabinerelated myelosuppression toxicity, no additional patients were enrolled in accordance with the CRM algorithm. Pevonedistat dose de-escalation to 15 mg/m 2 was not explored, as myelosuppression was considered related to gemcitabine. The MTD of pevonedistat in combination with gemcitabine was not determined, and this drug combination was abandoned.
Of 15 patients with cycle 1 DLTs, 10 had liver function test (LFT) elevations (increased AST/ALT), which were the predominant DLTs reported across all arms regardless of standard-of-care chemotherapy. All LFT elevations were without clinical sequelae and reversible with dose delays or holds; prior therapies for these patients are reported in the Online Resource: Supplementary Table 2 .
Safety
All 64 patients experienced ≥1 AE and 53 (83%) had grade ≥3 AEs ( Table 3 ). The most common any-grade AEs were fatigue (56%), nausea (50%), anemia (41%), constipation, diarrhea (34% each), increased AST (31%), and vomiting (30%). The most common grade ≥3 AEs were decreased neutrophil count (22%) and increased AST (20%). Overall, 95% of patients had ≥1 drug-related AE of any grade and 66% had grade ≥3 drugrelated AEs (Online Resource: Supplementary Table 3) . Across arms, 26 (41%) patients experienced ≥1 serious AE, including febrile neutropenia (9%), dyspnea (6%), abdominal pain, and pneumonia (3% each).
Four patients (arm 2) reported AEs leading to permanent treatment discontinuation. Of these, one patient receiving pevonedistat 15 mg/m 2 in combination with carboplatin plus 
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance score; NSCLC, non-small cell lung cancer a Includes 12 patients with adenocarcinoma and one with large cell adenocarcinoma b Includes one patient with parotid gland carcinoma (arm 2), one with salivary gland carcinoma (arm 1), and one with squamous cell carcinoma of the oropharynx (arm 2)
paclitaxel discontinued due to thrombocytopenia, and three patients (two receiving pevonedistat 20 mg/m 2 and one 25 mg/m 2 , both with carboplatin plus paclitaxel) discontinued due to peripheral neuropathy or peripheral sensory neuropathy.
There were five on-study deaths, including one on day 23, cycle 1 that was considered drug-related (arm 3, pevonedistat 25 mg/m 2 : febrile neutropenia). A further three patients died during cycle 1 and one died during cycle 9, all of which were considered unrelated to treatment (all pevonedistat 25 mg/m 2 ; one each in arm 1 and arm 2, two in arm 3). Figure 1 compares the dose-normalized pevonedistat concentrations for patients receiving pevonedistat in combination with docetaxel (n = 16, dose-escalation; n = 6, MTD expansion), carboplatin plus paclitaxel (n = 20 dose-escalation; n = 6, MTD expansion), or gemcitabine (n = 10) with those from patients who received single-agent pevonedistat in previous studies [7] [8] [9] 11] . Examination of individual patient plasma concentration-time data (Fig. 1a and c) revealed no significant changes in pevonedistat pharmacokinetics when given with docetaxel (arm 1) or gemcitabine (arm 3), as the observed pevonedistat concentrations in the presence of docetaxel or gemcitabine showed considerable overlap with those with pevonedistat alone. By contrast, following the end of infusion and throughout the 48-h sampling period, pevonedistat plasma concentrations were consistently higher in patients receiving carboplatin plus paclitaxel than in patients receiving single-agent pevonedistat (Fig. 1b) .
Pevonedistat pharmacokinetics
Disease response
A summary of best response to treatment is shown in Table 4 . In arm 1, among 19 response-evaluable patients, three patients receiving the MTD achieved a partial response (PR), for an overall response rate (ORR) of 16%. Among responders, one (15) 1 (10) Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase had cholangiocarcinoma, two had head and neck cancer (squamous cell carcinoma and salivary gland carcinoma), and all three had lung metastases. One patient in arm 2a (squamous cell carcinoma of the head and neck not otherwise specified) achieved a PR.
In arm 2, among 23 response-evaluable patients, eight patients achieved a PR or complete response (CR; ORR 35%). Two patients with bladder cancer and endometrial cancer receiving pevonedistat 20 mg/m 2 (MTD) achieved a CR; at data cutoff, the duration of CR was 8.1 and 8.5 months (9 and 11 cycles), respectively. At the time of reporting, both patients remained on study (cycle 43+ representing the longest treatment duration) receiving single-agent pevonedistat since cycle 9 and 13, respectively. Of the six patients achieving PRs in arm 2, two received pevonedistat 25 mg/m 2 and four received pevonedistat 20 mg/ m 2 ; all six had progressive disease after PR. Median duration of response (DOR) for the 12 patients achieving a CR or PR across both arms was 5.9 months (range, 0.03-12.02). Median DOR for the eight patients receiving pevonedistat with carboplatin and paclitaxel (arm 2) was 7.4 months (range, 2.37-12.02). Across 54 responseevaluable patients, 41 achieved stable disease or better (≥SD), of whom 25 received treatment for ≥5 cycles (eight in arm 1, 15 in arm 2, and two in arm 3), with the longest treatment duration being 21 cycles at data cutoff (arm 2, chondrosarcoma). At the pevonedistat MTDs, 10 of 16 patients in arm 1 (25 mg/m 2 ) and all 12 patients in arm 2 (20 mg/m 2 ) achieved ≥SD; of these, six and nine patients, respectively, received study treatment for ≥5 cycles.
Prior therapies in patients achieving a response are presented in the Online Resource: Supplementary Table 4 . Of 12 patients achieving a CR or PR, 10 had received prior platinum therapy. None of the responders in arm 1 (pevonedistat plus docetaxel) had received prior docetaxel, and one patient had received prior carboplatin plus paclitaxel. By contrast, all but one patient achieving a CR or PR in arm 2 (pevonedistat in combination with carboplatin and paclitaxel) and one responder in arm 2a (pevonedistat plus carboplatin) had received ≥1 course of platinum and/or taxane. In arm 2, four patients had received both taxane and platinum as prior therapies.
ERCC1 expression
ERCC1 expression levels were determined by calculating the H-score in patients receiving pevonedistat 20 mg/m 2 or 15 mg/m 2 in arm 2 and arm 2a. The median H-score for all ERCC1-evaluable patients (n = 21) was 170 (range, 65-290), which served as the cutoff to classify patients into ERCC1 high (H-score > 170, n = 10) and low (H-score ≤170, n = 11) expression level groups. High ERCC1 expression appeared to correlate with clinical benefit (CR/PR/SD duration ≥5 cycles; Fig. 2a ). There was a trend for patients with high ERCC1 levels to remain on study longer than patients with low ERCC1, with a median time on study of 10.5 and 4.7 months, respectively (Fig. 2b) .
Discussion
This phase Ib study was the first to investigate the safety and tolerability of pevonedistat plus standard-of-care chemotherapies in patients with advanced solid tumors. The MTD for pevonedistat was determined to be 25 mg/m 2 with docetaxel and 20 mg/m 2 with carboplatin plus paclitaxel. The combination of pevonedistat plus gemcitabine was deemed intolerable due to two patient withdrawals and one on-study death (febrile neutropenia), and based on patients missing ≥1 treatment dose ( c y c l e 1 ) o r e x p e r i e n c i n g g e m c i t a b i n e -r e l a t e d myelosuppression which led to dose delays in cycle 2. Therefore, enrollment into this cohort ceased. The most frequently reported DLTs across all arms included grade 3 febrile neutropenia and increased ALT/AST; AST/ALT elevations were reversible with dose holds, reductions, or delays.
The safety profile of pevonedistat plus docetaxel or carboplatin plus paclitaxel was generally favorable.
Common AEs reported in this study (fatigue, nausea, anemia, constipation, and diarrhea) were similar to those previously observed in patients receiving standard-of-care chemotherapies [27] [28] [29] . With dose reductions or delays, repeat dosing of pevonedistat plus docetaxel or pevonedistat in combination with carboplatin plus paclitaxel was feasible in patients with solid tumors, and at the time of reporting, two patients (arm 2) remained on study receiving single-agent pevonedistat 20 mg/ m 2 (currently cycle 43+). Pevonedistat treatment did not appear to result in additional toxicity when added to standard-ofcare chemotherapy, and there was no cumulative toxicity from pevonedistat despite prolonged treatment.
Evaluation of concentration-time data from 58 patients for whom blood samples were available revealed that the pharmacokinetic profile of pevonedistat was unchanged in the presence of docetaxel or gemcitabine compared with historical single-agent pevonedistat pharmacokinetic data [7] [8] [9] 11] . There was a trend toward higher pevonedistat plasma concentrations when given with carboplatin plus paclitaxel, compared with single-agent administration. This apparent drugdrug interaction effect, which cannot be explained at this time, warrants further investigation. Although some overlap exists in the metabolizing enzymes and/or transporter proteins involved in the drug clearance of pevonedistat and the standard-of-care agents, none are known inhibitors or inducers. A radiolabeled mass balance study is ongoing to characterize the clearance pathways of pevonedistat in humans (ClinicalTrials.gov identifier NCT03057366). Additionally, because of the limited pharmacokinetic sampling scheme (13) 1 (17) Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease a Tumor types: bladder carcinoma (patient received prior platinum therapy) and endometrial cancer (patient received both platinum and taxane as prior therapy) b Tumor types: biphasic hepatocellular carcinoma and cholangiocarcinoma, breast cancer, cholangiocarcinoma, follicular dendritic cell sarcoma, salivary gland carcinoma, squamous cell carcinoma of the head and neck not otherwise specified, squamous cell carcinoma of the oropharynx, squamous non-small cell lung cancer, and parotid gland carcinoma used in this study, individual concentration-time data will be pooled with other study data and analyzed using a population modeling approach to quantify the observed effects of carboplatin and paclitaxel on pevonedistat pharmacokinetics. The combination of pevonedistat with carboplatin plus paclitaxel (arm 2) showed the most promising broad-based antitumor activity in pretreated patients (≥1 prior therapies). Notably, all but one of the eight responders in arm 2 and one responder in arm 2a had previously received platinum, taxanes, or both. The ORR in arm 2 was 35%, including two patients with CR (bladder cancer and endometrial carcinoma). These two patients discontinued carboplatin plus paclitaxel chemotherapy at cycle 9 and 13, respectively, and went on to maintenance therapy with single-agent pevonedistat; both patients are currently continuing treatment in cycle 43 without evidence of disease. Consistent with preclinical studies reporting synergy between pevonedistat and standard-of-care chemotherapy [13, 24] , the long treatment durations in this study and objective responses in patients resistant to prior platinum/taxane therapy suggest the potential reversal of resistance by the addition of pevonedistat. Further exploration of pevonedistat and carboplatin plus paclitaxel in the platinum-and/or taxane-resistant setting is warranted.
Pevonedistat was shown in model systems to synergize with platinum-containing agents by interfering with NER and ICR pathways [13] . Previous studies reported that low ERCC1 expression is associated with clinical benefit in advanced cancer patients receiving platinum-based chemotherapy [19] [20] [21] . Interestingly, in our study, patients receiving pevonedistat plus paclitaxel and carboplatin, who had high ERCC1 expression appeared to show greater clinical benefit and remained on study longer than those with low ERCC1 expression. Further investigations are warranted to provide insight into this observation, which suggests the possibility that pevonedistat might re-sensitize patients to platinumbased chemotherapy and provide a potential new approach to therapy in these patients.
The observed clinical benefit in patients treated in arm 2, especially in patients with prior taxane and/or platinum exposure, supports further investigation of pevonedistat with carboplatin plus paclitaxel in phase II trials. 
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